UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Tag: drug discovery

Harvesting the power of the cell’s own protein degradation mechanisms in drug discovery

Constant production of proteins in living cells is subject to strict quality and concentration control. The ubiquitin-protease system (UPS) is one of the systems responsible for degrading misfolded and damaged proteins. Also, short-lived regulatory proteins that control many critical cellular processes, including cell cycle progression, cell proliferation and differentiation, cell signalling and transcription are degraded by UPS.1

Read More

How deep learning is transforming medical imaging: image search

Five or six years ago, I was looking for a strategic direction for the KIMIA Lab. We started with the problems. We asked, ‘What problems do we have in medical imaging?’ 

Read More

PROTAC drug discovery – prior preparation and planning

“By failing to prepare, you are preparing to fail” so said Benjamin Franklin, and as a veteran of early stage drug discovery you can bet that I, like you, have seen my fair share of successes but also more failures than I’d like.  

Read More

Slides from the 4th Medicinal Chemistry & Protein Degradation Summit

The 4th Medicinal Chemistry & Protein Degradation Summit provided two days of fascinating topics and case studies about AI-assisted lead optimisation, DNA encoded libraries and the use of data and informatics in drug-discovery. We have made the following presentation slides available from Greg Makara, Paul Colbon and Yugal Sharma.

Read More

Reshaping drug discovery with deep learning and polypharmacology

Cyclica is a Toronto-based biotech that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. We spoke to their Chief Scientific Officer Andreas Windemuth.

Read More

Will the intersection of blockchain and AI inspire the Pharma R&D Renaissance?

Global Engage spoke to Scott Kahn ahead of the 3rdGlobal Pharma R&D Informatics and AI Congress. Scott is the CIO of Luna PBC, the entity that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.

This is the second half of that conversation, where Scott discusses the challenges of distributive ledger technologies such as Blockchain, and their intersection with AI for Pharma R&D.

Read More

How to revolutionise clinical trials: engaging with participants as partners

Ahead of the 3rd Global Pharma R&D Informatics and AI Congress, Global Engage spoke to Scott Kahn, CIO of LunaPBC. LunaPBC is the company that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.

In the first half of the conversation, Scott discusses the benefits of distributive ledger technologies such as Blockchain for Pharma R&D.

Read More

Why drug designers will be at a disadvantage without AI

We spoke to John Griffin, CSO at Numerateto find out how AI is changing drug discovery and development. Numerate is a drug design company applying cutting-edge AI to transform the process of small molecule drug design.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Archive